Pluri (PLUR) Granted U.S Patent for New Method
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
April 8, 2024 7:00 AM EDTPluris patent enables mass-scale production of immune cell therapiesNew patented technology is applicable for the expansion of a variety of immune cellsTechnology sets stage for potential immune cell therapy advancements and targets an estimated total addressable market of $11.66 billion by 2030
HAIFA, Israel, April 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company, Pluri Inc. (Nasdaq: PLUR) (TASE:... More
